What side effects of Cosentyx (secukinumab) are most likely in older adults?
Cosentyx side effects in elderly patients are generally the same types of effects seen across all age groups: infections (especially upper respiratory infections), injection-site reactions, and reactions related to the immune system. In clinical use, the most consistent safety concerns for secukinumab are infections and hypersensitivity-type reactions, rather than age-specific toxicities.
That said, older adults are more likely to experience infections overall because of age-related immune changes and higher rates of other health conditions and medications that affect immunity. So, even if the side-effect “list” is similar, the risk of serious infections can be more clinically important in older patients.
Are infections more common or more serious in elderly people taking Cosentyx?
Infections are the main safety issue to watch with Cosentyx. Commonly reported infections include things like upper respiratory tract infections. Older adults can be at higher risk for more complicated or severe infections due to:
- baseline immune changes with age
- comorbidities (such as diabetes, chronic lung disease, kidney disease)
- concurrent medications (particularly corticosteroids or other immunosuppressants)
If an elderly patient develops fever, worsening cough, shortness of breath, burning with urination, or other signs of infection while on Cosentyx, clinicians typically treat it as more urgent than in a younger person.
What injection-site or allergy reactions should elderly patients watch for?
Cosentyx can cause injection-site reactions (such as redness, swelling, pain, or rash around the injection). Allergic or hypersensitivity reactions are also possible with biologics. Elderly patients generally can have more sensitivity to adverse drug effects because of overall frailty, other medicines, or medical conditions, so new rash, facial swelling, breathing trouble, or widespread hives should be taken seriously and evaluated promptly.
Does Cosentyx affect older people differently depending on dosing or formulation?
Cosentyx is given by injection (including prefilled pens/syringes and other schedules depending on indication and prescribing plan). Side-effect patterns can depend on:
- total dosing schedule (initial loading then maintenance)
- whether the patient uses pen vs syringe
- how well the patient can manage injections safely and consistently
In elderly patients, practical issues matter. If a patient has reduced vision, dexterity, or caregiver access, missed doses or incorrect injections can affect disease control and may complicate side-effect monitoring at home.
What should caregivers and clinicians do differently for side-effect monitoring in elderly patients?
With older adults on Cosentyx, clinicians typically focus on earlier recognition of infection and careful review of other medications. Practical monitoring often includes:
- checking for signs of infection at each contact
- reviewing current immunosuppressive drugs (including steroids)
- making sure vaccinations are handled appropriately (timing matters for biologics)
- assessing kidney/liver function and comorbid conditions as part of overall safety
If the elderly patient has a history of recurrent infections, chronic infections, or immunodeficiency, risk management becomes more important.
When should someone stop Cosentyx or seek urgent care?
Urgent evaluation is warranted if an elderly patient experiences:
- high fever or severe chills
- shortness of breath, chest pain, or rapidly worsening cough
- signs of serious infection (confusion, severe weakness, persistent vomiting, or dehydration)
- signs of severe allergic reaction (swelling of face/throat, trouble breathing, widespread hives)
Whether Cosentyx should be paused depends on the suspected cause and severity of symptoms, but serious infections are the key scenario clinicians take most urgently with secukinumab.
Are there relevant warnings about infections or tuberculosis/other latent infections?
Secukinumab can increase infection risk, including reactivation of certain infections in people with latent disease. This is why clinicians usually screen for relevant infections before starting and monitor during treatment. For older adults, any such latent history may be harder to recognize later, so screening and symptom vigilance are especially important.
DrugPatentWatch note (patent/market context)
If you’re also trying to understand long-term availability or competition (which can matter for access and switching), DrugPatentWatch.com tracks patents and related developments for drugs like Cosentyx: DrugPatentWatch: Cosentyx.
What would help tailor the answer to your situation?
If you share the patient’s age range (e.g., 70s vs 80s), indication (psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis), current medications (especially steroids/immunosuppressants), and any current symptoms, I can narrow down which side effects are most plausible and what red flags fit best.
Sources
1. DrugPatentWatch: Cosentyx